1 Title: Plasma cell-free DNA as a prognostic biomarker in small cell lung cancer

2 patients

3

4 Authors:

5 Patricia Mondelo-Macía^{1,2}, Jorge García-González^{3,4,5}, Alicia Abalo¹, Manuel
6 Mosquera-Presedo², Rafael López-López^{3,4,5}, Luis León-Mateos^{*3,4,5}, Laura Muinelo7 Romay^{*1,5}, and Roberto Díaz-Peña^{*1,6}.

8

9 Affiliations:

1 10 Liquid Biopsy Analysis Unit, Translational Medical Oncology (Oncomet), 11 Health Research Institute of Santiago (IDIS), Santiago de Compostela, Spain. 2 12 Universidade de Santiago de Compostela (USC), Santiago de Compostela, 13 Spain. 14 Department of Medical Oncology, Complexo Hospitalario Universitario de 15 Santiago de Compostela (SERGAS), Santiago de Compostela, Spain. 4 16 Translational Medical Oncology (Oncomet), Health Research Institute of 17 Santiago (IDIS), Santiago de Compostela, Spain. 5 18 Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, 19 Spain.

- ⁶ Facultad de Ciencias de la Salud, Universidad Autónoma de Chile, Talca, Chile
 ²¹
- ^{*}These authors contributed equally to this work.
- 23
- 24

25 **Correspondence**:

- 26 Luis León-Mateos, MD (luis.Angel.Leon.Mateos@sergas.es, ORCID: 0000-0002-0742-
- 27 1209), Laura Muinelo-Romay, PhD (lmuirom@gmail.com, ORCID: 0000-0002-7456-
- 28 7531), Roberto Díaz Peña, PhD (roberto.diaz.pena@sergas.es, ORCID: 0000-0002-
- 29 0114-2292). Address: Complexo Hospitalario Universitario de Santiago de Compostela,
- 30 Travesía da Choupana s/n; 15706, Santiago de Compostela, Spain

31 **Keywords:** Small cell lung cancer; liquid biopsy; cell free DNA; circulating tumor 32 cells; prognostic biomarkers.

34 ABSTRACT

35 <u>Background</u>: Lack of biomarkers for treatment selection and monitoring in small-cell 36 lung cancer (SCLC) patients with the limited therapeutic options, result in poor 37 outcomes. Therefore, new prognostic biomarkers are needed to improve their 38 management. The prognostic value of cell-free DNA (cfDNA) and circulating tumor 39 cells (CTCs) have been less explored in SCLC.

40 <u>Methods</u>: We quantified cfDNA in 46 SCLC patients at different times during therapy.

- 41 Moreover, CTCs were analyzed in 21 patients before therapy onset using CellSearch®
 42 system. Both biomarkers were associated with patients' outcomes and a prognostic
 43 model was developed.
- 44 Results: High cfDNA levels before therapy were associated with shorter progression-45 free survival and overall survival. Furthermore, changes in cfDNA levels between baseline and 3 weeks and cfDNA levels at progression disease were also associated with 46 47 patients' outcomes. Multivariate analyses confirmed the independence of cfDNA levels 48 as a prognostic biomarker. Finally, the three-risk category prognostic model developed 49 included ECOG Performance Status, gender and baseline cfDNA levels was associated 50 with a higher risk of progression and death. 51 Conclusions: We confirmed the prognostic utility of cfDNA in SCLC patients before
- and during therapy. Our novel risk prognostic model in clinical practice will allow to
 identify patients who could benefit with actual therapies.

55 INTRODUCTION

56 Small-cell lung cancer (SCLC), which accounts for 15% of all lung cancer cases, is 57 characterized by its aggressiveness, its strong association with tobacco and the poor 58 outcome. About 70% of patients present extensive disease (ED-SCLC) where only 2% 59 survive 5 years after diagnosis (1-3). For many years, chemotherapy was the unique 60 option to treat this tumor type. However, the scenario has changed in the last years (3). 61 New therapies, such as immunotherapy, have been recently incorporated into the 62 management of SCLC patients and, although some survival improvements have been 63 reported in the patients with ED-SCLC (4–8), the majority of them do not benefit from 64 this new treatment (9). The genomic profile of SCLC is characterized by extensive 65 chromosomal rearrangements and a high mutational burden, including in nearly all, inactivation of the tumor suppressor genes TP53 and RB1 (10). However, nowadays the 66 67 selection of treatment in SCLC patients is not dependent on the characteristics of the tumor (11), and the criteria to stratify patients is not clear, since no predictive 68 69 biomarkers have been validated for the clinical practice (12). In this context, the use of 70 liquid biopsies as a tool to guide treatment and/or for monitoring the patients' response 71 represent a valuable alternative (13).

Circulating tumor DNA (ctDNA), derived from tissue tumor cells, has demonstrated its clinical utility and represents a promising tool for guiding precision medicine in several cancer types (14,15). In SCLC, different studies have investigated the importance and the clinical value of analyzing ctDNA levels. However, driver mutations known in SCLC are limited to *RB1* and *TP53* genes (16). In contrast, total cell-free DNA (cfDNA) consists of a heterogeneous and complex DNA fraction released in body fluids by any cell type through cell death mechanisms (17,18). The short half-life of cfDNA

enables real-time monitoring for response or relapse, being an easy-to-implementbiomarker to monitor cancer evolution and response to therapy (19).

81 Circulating tumor cells (CTCs) are another frequent circulating biomarker investigated 82 in cancer. As a high metastatic tumor type, SCLC is characterized by a strong release of 83 CTCs, with detection rates of 60.2%-94% (16), suggesting that CTCs could be 84 employed as a disease surrogate in SCLC. The analysis of CTCs originated from the 85 primary or metastatic sites (20) as a prognostic biomarker has been reported in different 86 cancer types (21–23) including SCLC. However, the prognostic threshold in SCLC has 87 been not well established (24–28). Despite their different nature, the combined analysis 88 of total cfDNA and CTCs in patients with SCLC could provide complementary 89 information for improving SCLC patients' management.

90 In this study, we hypothesized that total cfDNA levels can serve as a useful biomarker 91 for prognostic and follow-up of SCLC patients under first line of therapy. For this 92 purpose, we analyzed the total cfDNA levels in a cohort of 46 patients with SCLC prior 93 to the start of therapy, at 3 weeks after the first dose, and at the time of progression of 94 the disease. The additional value of CTCs was investigated in our cohort in order to 95 provide a more complete view of the disease dynamics. To our knowledge, this study is 96 the first to examine the possible role of total cfDNA levels as a prognostic and follow-97 up biomarker in SCLC patients.

99 **METHODS**

100 **Patients and blood sample collection**

101 Forty-six patients with new diagnosed SCLC who received first-line treatment between 102 June 2017 and June 2021, at the Department of Medical Oncology of Complexo 103 Hospitalario Universitario de Santiago de Compostela were enrolled in the study. In 104 total 111 blood samples were collected at different time points: before therapy onset 105 (baseline) (n=46), 3 weeks after therapy start (n=40) and at the progression of the 106 disease (n=25). A control cohort of 20 healthy individuals was also included in order to 107 select the better assay to quantify total cfDNA. All individuals signed informed consent 108 forms approved by Santiago de Compostela and Lugo Ethics Committee (Ref: 109 2017/538) prior to enrolling in the study and could withdraw their consent at any time. 110 The study was performed in accordance with the Declaration of Helsinki.

111 **Clinical endpoints**

Progression-free survival (PFS) was defined as the time from the date of initial treatment until the date of progression disease, death or last follow-up, whichever occurred first. Progression date was defined as the date of disease progression based on RECIST (v.1.1), or the date of clinical progression if the patient discontinued the treatment due to clinical deterioration despite not meeting criteria for RECIST progression. Overall survival (OS) was defined as the time from the date of initial treatment to the date of death or the last date of follow-up.

119 Sample processing and cell free DNA isolation

Peripheral blood was obtained by direct venepuncture in CellSave tubes (Menarini, Silicon Biosystems, Bologna, Italy) and processed within 96 hours after blood collection. Plasma and cellular components were separated by centrifugation at 1,600 g for 10 minutes at room temperature. Plasma was centrifugated a second time at 5,500 g

for 10 minutes at room temperature in order to remove any remaining cellular debris and aliquoted for storage at -80 °C until the time of cfDNA extraction. cfDNA was isolated from 3 mL of plasma using the QIAamp Circulating Nucleic Acid Kit (Qiagen, Hilden, Germany) using a vacuum pump, according to the manufacturer's instructions and eluted in LoBind[®] tubes (Eppendorf AG, Hamburg, Germany).

129 Total cell free DNA quantification

130 CfDNA levels were quantified using two different approaches: Qubit 4 Fluorometer 131 (ThermoFisher Scientific, Waltham, MA, USA) and quantitative PCR (qPCR) method 132 by analyzing the telomerase reverse transcriptase (*hTERT*) single-copy gene (Thermo 133 Fisher Scientific, Waltham, MA, USA).

134 $2 \mu L$ of the sample were employed to quantify by the fluorometric instrument Qubit 4

using the Qubit dsDNA HS Assay Kit (ThermoFisher Scientific, Waltham, MA, USA).

136 In the other hand, samples were quantified by a qPCR assay, described previously (29).

137 Briefly, each qPCR reaction was carried out in a final volume of 20 µL: 10 µL of 138 TaqMan Universal Mastermix (Thermo Fisher Scientific, Waltham, MA, USA), 1 µL of 139 hTERT hydrolysis probe and 2 μ L of the sample. Each sample was analysed in 140 duplicate. In addition, each plate included a calibration curve and negative controls. The 141 calibration curve calculated based on a dilution series of a commercial standard human 142 genomic DNA (Roche Diagnostics, Mannheim, Germany), was fragmented in 184 bp 143 using Covaris[®] E220 Focused-ultrasonicator (Covaris, Massachusetts, USA) using the 144 following protocol: 430s duration, peak incident power of 175 Watts, duty factor of 145 10% and 200 cycles per burst. Fragments size were then determined using a TapeStation 4700 (Agilent, Santa Clara, CA, USA) and the High Sensitivity DNA 146 147 ScreenTape[®] (Agilent, Santa Clara, CA, USA). Amplification was performed under the following cycling conditions using a QuantStudioTM 3 real-time PCR system (Thermo 148

149 Fisher Scientific, Waltham, MA, USA): 50 °C for 2 min; 95 °C for 10 min; 40 cycles of 95 °C 15 s; and 60 °C for 1 min. Data were analyzed with QuantStudioTM Design & 150 151 Analysis software, version 2.5.1 (Thermo Fisher Scientific, Waltham, MA, USA). 152 The final concentration of each sample was calculated by interpolation of the mean of 153 cycle quantification values (Cq) with the calibration curve. Values with a Cq confidence interval less than 0.95 were discarded. Moreover, only assays with R² values greater 154 155 than 0.98 for the standard curve and with an efficiency $\geq 88.8\%$ were used. Results 156 obtained from both approaches (Qubit vs hTERT qPCR) were compared.

157 **CTC detection and enumeration**

158 Circulating tumor cell analyses were performed using the CellSearch® system 159 (Menarini, Silicon Biosystems, Bologna, Italy). Peripheral whole blood of each patient 160 was collected in CellSave preservative tubes (Menarini, Silicon Biosystems, Bologna, 161 Italy), stored at room temperature and processed within 96 hours after the blood was 162 drawn.

163 Briefly, 7.5mL of whole blood were mixed with 6mL of buffer and centrifugated at 800 164 g for 10 minutes at room temperature. Next, samples were processed in the CellTracks 165 Autoprep system using the Circulating Tumor Cell Kit (Menarini, Silicon Biosystems, 166 Bologna, Italy). The kit consists of ferrofluids coated with epithelial cell-specific anti-167 EpCAM antibodies to immunomagnetically enrich epithelial cells; a mixture of 168 antibodies directed to cytokeratins (CKs) 8, 18, and 19 conjugated to phycoerythrin 169 (PE); an antibody to CD45 conjugated to allophycocyanin (APC); nuclear dye 4',6-170 diamidino-2-phenylindole (DAPI) to fluorescently label the cells as well as buffers to 171 fix, permeabilize, wash and resuspend the cells. Finally, samples were analyzed with the 172 CellTracks Analyzer II according to the manufacturer's instructions. The CTCs were

identified as round or oval cells with an intact nucleus (DAPI⁺), CK positive and CD45

174 negative.

175 Statistical analysis

176 Continuous data were summarized as mean, median and range whereas frequency and 177 percentage were presented for categorical variables. Categorical variables were 178 compared using the chi-square test or Fisher's exact test. Swimmer plot was provided to 179 visualize the times of sample collection, every patient's therapy and clinical outcomes. 180 Pearson test was used to evaluate a pairwise correlation between the different strategies 181 to quantify the cfDNA, by fluorometry and qPCR. The Mann-Whitney-Wilcoxon U-182 Test was used to compare continuous variables between groups. Receiver operating 183 characteristics (ROC) curves were computed based on cfDNA levels of SCLC patients 184 and healthy controls, representing the area under the curve (AUC) values and 185 computing the confidence intervals (CI) at 95% confidence levels. ROC curves were 186 also constructed to evaluate the thresholds of baseline cfDNA levels for PFS and OS 187 analyses. Kaplan-Meier method was used to plot the survival curves applying the log-188 rank test. Univariate and multivariate Cox regression analyses were used to evaluate 189 factors independently associated with PFS and OS. A final prognostic model for PFS 190 and OS was developed. Comparisons of Cox proportional hazard regression models 191 were made using the Akaike information criterion (AIC) technique (30), with a smaller 192 AIC value indicating the better model. All statistical analyses were performed using R 193 version 4.1.1. The following R packages were used: survival (31), survminer, ggplot2 194 (32), pROC (33), gtsummary (34), swimplot, stats, rstatix.

195

196

198 **RESULTS**

199 Patient characteristics and sample collection

200 Forty-six SCLC patients were included in the study. Their clinicopathological 201 characteristics are presented in Table 1. The median age was 67 (range 47-83) years, all 202 the patients were current or former smokers, and most were males (84.78%) and stage 203 IV tumors (89.13%). The Eastern Cooperative Oncology Group Performance Status 204 (ECOG PS) <2 accounted for 67.39% of cases and 52.17% of patients had a number of 205 metastases ≥ 2 . The median number of chemotherapy or chemotherapy/immunotherapy 206 treatment cycles was 5 (range 1–11). At the time of analysis, 41 of the 46 (89.13%) 207 evaluable patients had experienced disease progression and 38 of the 46 (82.6%) 208 evaluable patients had died. Sample collection was performed before therapy onset, 3 209 weeks after initiation of therapy and at the time of progression disease (Figure 1). 210 Median PFS and OS were 174 (range 4-483) and 229 (range 4-748) days, respectively.

211 CfDNA levels are specifically increased in SCLC patients

212 In order to determine the better method to quantify the total cfDNA in patients with 213 SCLC, we compared the Qubit 4 Fluorometer (ThermoFisher Scientific, Waltham, MA, 214 USA) versus the qPCR method by analyzing the hTERT single-copy gene (Thermo 215 Fisher Scientific, Waltham, MA, USA). A good correlation between both approaches at 216 different times of therapy (baseline, 3 weeks, and progression disease) was found (\mathbb{R}^2 217 =0.959) (Figure 2A). In addition, 20 healthy controls were included in order to compare 218 their cfDNA levels with our patient cohort using both approaches. Total cfDNA levels 219 in healthy controls were statistically lower than in those found in the SCLC cohort (Wilcoxon test $p=1.2x10^{-08}$ and $p=1.5x10^{-11}$, using both fluorometer method and qPCR 220 221 assay, respectively) (Figure 2B-C). Our qPCR assay showed an AUC=0.95 (specificity 222 95% and sensibility 85%) whereas the fluorometer method presented an AUC=0.94

(specificity 100% and sensibility 80%) (Figure 2D-E). These results evidenced that cfDNA levels were increased as a result of the malignant disease in SCLC patients and reinforced their interest as a potential biomarker to follow-up the disease evolution. In addition, the PCR-based strategy was prioritized to quantify the cfDNA since this method appears as a more robust option than fluorometric quantification.

228 Clinical interest of cfDNA analysis at baseline

Total cfDNA was quantified by qPCR assay at different time points in our patient cohort with the goal to evaluate its potential as a monitoring tool (Supplementary Table 1). CfDNA levels at baseline were significantly higher in patients with stage IV cancer, poor performance status, an elevated number of sites of metastasis and presence of liver metastases (P value \leq 0.05) (Table 1). There was no statistically significant association with respect to age, gender, smoking status, presence of bone metastasis, presence of lymph node metastases and the treatment used.

236 In addition, the possible role of cfDNA as a prognostic biomarker before therapy in 237 SCLC was investigated. Thus, the cfDNA levels were log-transformed and the patients 238 were dichotomized into high and low cfDNA level groups based on ROC analysis 239 (Supplementary Table 2). The thresholds of baseline log cfDNA levels were chosen at 240 7.650 (~2100.65 copies in hG/mL plasma) and 8.077 (~3219.56 copies in hG/mL 241 plasma) for PFS and OS analyses, respectively. We found that patients with high levels 242 of total cfDNA at baseline presented shorter PFS (long rank p=0.0005, hazard ratio, 243 5.06; 95% CI 1.89–13.6) and OS (long rank p=0.0005, hazard ratio, 3.32; 95% CI 1.50-244 7.37) than those with low levels of total cfDNA (Figure 3A-B). The median PFS of 245 patients in the low baseline cfDNA group was 350 days versus 156 days in the high 246 baseline cfDNA group, whereas the median OS was 426 and 210 days in the two 247 respective groups (low vs high baseline total cfDNA levels). Univariate and

multivariate Cox regression analyses of PFS and OS were performed considering various clinical and demographic variables (ECOG PS, sex, age, stage, number of metastases, presence of liver metastasis and smoking status) (Table 2). Multivariate regression analyses confirmed the value of the cfDNA levels at baseline as an early independent predictor biomarker for PFS and OS (hazard ratio, 46.0; 95% CI, 3.16-672; p-value =0.005 and hazard ratio, 32.4; 95% CI, 3.05-344; p-value =0.004, respectively).

254 Longitudinal analysis of total cfDNA levels during therapy

255 To determine whether cfDNA levels can be employed to monitor patients' evolution 256 during therapy, we quantified longitudinal cfDNA levels at 3 weeks after initiation of 257 treatment (n=40) and at progression disease (n=25). We found that levels of total 258 cfDNA were significantly higher before therapy than at 3 weeks after therapy onset 259 (Wilcoxon test p = 0.002; Supplementary Figure 1), suggesting clearance of ctDNA 260 after therapy start which impact on cfDNA levels. However, no significant differences 261 between cfDNA levels at baseline and at progression disease were found 262 (Supplementary Figure 1).

263 To analyze the possible prognostic role of cfDNA monitoring during therapy, cfDNA 264 levels were also log-transformed and the patients were dichotomized into high and low 265 cfDNA level groups based on ROC analysis (Supplementary Table 2) in each sample 266 time. Thus, the possible prognostic role of monitoring cfDNA levels at 3 weeks after 267 initiation of treatment was investigated. We divided our cohort into groups after 268 considering their changes in cfDNA levels: Favorable group (patients with low cfDNA 269 levels at baseline and at 3 weeks + patients with high cfDNA levels at baseline but low 270 levels at 3 weeks; n=18) and unfavorable group (patients with low cfDNA levels at 271 baseline but high cfDNA levels at 3 weeks + patients with high cfDNA at baseline and 272 at 3 weeks; n=22). Patients for the unfavorable group showed a shorter PFS (long rank

273 p<0.0005, hazard ratio, 3.5; 95% CI 1.69-7.23) and OS (long rank p<0.0005 hazard 274 ratio, 3.67; 95% CI 1.72-7.82) (Figure 3C-D) than the favorable group. Multivariate 275 regression analyses confirm the independence of the cfDNA changes between baseline 276 and 3 weeks as a prognostic biomarker of PFS and OS (hazard ratio, 3.49.0; 95% CI, 277 1.50-8.12; p-value =0.004 and hazard ratio, 4.35; 95% CI, 1.68-11.3; p-value =0.002, 278 respectively) (Table 2). 279 Finally, cfDNA quantification at the time of progression disease was performed in 25

280 SCLC patients. Our results reported that patients with high cfDNA levels at this time

point survive fewer days than patients with low cfDNA levels (long rank p < 0.0001,

hazard ratio, 15.2; 95% CI 3.28-70.7; 426 days in the high cfDNA levels group versus

283 214 days in the low cfDNA levels group) (Figure 3E).

284 Circulating tumor cells analyses and prognostic value

CTCs analyses were performed in 21 patients with SCLC before starting the treatment. 85.71% of patients (18 of 21 patients) presented at least 1 CTC with a median of 26 CTCs (range 0 – 4796) (Supplementary Figure 2A-B). CTCs number at baseline was significantly higher in patients with extensive disease (stage IV) and with poor performance status (Supplementary Figure 3A-J). Also, the presence of CTCs and high cfDNA levels were significantly associated (Supplementary Figure 3K), indicating that both markers are reflecting the tumor burden.

In another hand, different cut-offs were analyzed in order to determine the possible prognostic value of CTCs (Supplementary Table 3). We found that the presence of \geq 150 CTCs/7.5mL of blood was significantly associated with shorter PFS rates (long rank p=0.02, hazard ratio, 4.66; 95% CI 1.11-19.6) in our cohort (Supplementary Table 3; Supplementary Figure 2C). In multivariate analysis CTCs did not show value as an independent predictive biomarker of PFS and OS.

298 **Prognostic model for PFS and OS**

299 An independent prognostic model for both PFS and OS was developed. Three variables 300 were retained in the final prognostic model: cfDNA levels (high vs. low levels), ECOG 301 PS (<2 vs. ≥ 2) and sex (male vs. female). The detailed results of the multivariate 302 analyses are shown in Figure 4A. Subsequently, we segregated patients into three risk 303 categories: patients with all adverse prognostic factors were classified in the poor-risk 304 category (high cfDNA levels, ECOG PS≥2 and male gender), patients with two adverse 305 prognostic factors were classified in the intermediate-risk category, and patients with 306 one or none adverse prognostic factor were classified in the favorable-risk category. The 307 Kaplan-Meier curves representing the three risk categories and median PFS and OS are 308 presented in Figure 4B-C. Median PFS ranged from 124 to 289 days based on the 309 number of adverse prognostic factors present before therapy. Median OS ranged from 310 115 to 514 days.

Going up from a lower category (favorable) to upper categories (intermediate and poor), the progression model quintuples the risk of disease recurrence (HR= 5.37, 95% CI, 2.32-12,4; p-value= $3x10^{-5}$) and six folds the risk of death (HR= 6.02, 95% CI, 2.66-13.6; p-value= $3x10^{-6}$) (Supplementary Table 4).

315

316 **DISCUSSION**

Precision medicine has the objective of optimizing the selection of the best therapy for each patient. In this context, liquid biopsy has emerged as a promising and minimally invasive tool for this due to its ability to provide a total image of primary and metastatic tumors at different times across therapy (35). Recently, the management of SCLC has changed and new therapies, such as immunotherapy among others, are been investigated and approved for clinical use (16,36,37). Nevertheless, the necessity to find a prognostic

323 biomarker for helping to select the therapy prescribed and to monitor the evolution of 324 the disease during the treatment, remains a challenge in SCLC patients. In this study, we 325 report for the first time the possibility to employ the cfDNA and its quantification as a 326 prognostic biomarker in SCLC prior to starting therapy and at different time points. Our 327 analyses allow us to identify a group of low-risk patients characterized by low cfDNA 328 levels at baseline who probably will benefit from both: chemotherapy in monotherapy 329 or the combination of immunotherapy and chemotherapy. The study of another common 330 circulating biomarker, CTCs, also provided us information for the prognostic of patients 331 before starting therapy, although the results were less clear. We found a significant 332 association between presence of a high number of CTCs (≥ 150 CTCs) and worse PFS.

333 Total cfDNA refers to a heterogeneous and complex DNA fraction free released in body 334 fluids by any cell type (not only tumoral) through several cell death mechanisms such as 335 secretion, apoptosis and necrosis (17,18). In line with our results, it's well reported that 336 cancer patients present higher cfDNA levels than healthy controls (38,39) but few 337 studies have investigated the possible prognostic and predictive value of total cfDNA 338 quantification in patients with SCLC. In contrast, the ctDNA, the tumor-derived fraction 339 of this cfDNA, has been reported as a prognostic and predictive biomarker in several 340 works (40-44). Almodovar et al. reported that changes in the mutant allele frequencies 341 on ctDNA were associated with response to treatment and relapse. Twenty-seven 342 patients with SCLC were analysed by next-generation sequencing (NGS) custom panel, 343 however, the lack of driver mutations known in SCLC, limited the number of genes 344 analyzed (40). In another work, Devarakonda et al analyzed 564 patients using a larger 345 NGS panel, including 73 genes, and, according to previous results into the bibliography, 346 RB1 and TP53 were the most frequent mutant, however, any prognostic or predictive 347 value was reported in this study.

In this way, total cfDNA quantification allows to detect the total DNA released from normal and also tumor cells into the blood. Thus, despite the few known driver mutations found in SCLC, cfDNA quantification allows to quantify the total levels before treatment and monitor the changes during therapy. Recently, our group demonstrated the feasibility to quantify cfDNA levels in non-small cell lung cancer patients and its association with patients' outcomes (45), suggesting its possible utility in SCLC.

355 Thus, in the present work, we quantified total cfDNA levels using two different 356 technologies, a fluorometric assay Qubit and a more specific assay, the qPCR assay 357 analyzing the *hTERT* gene. CfDNA levels quantified by both technologies showed good 358 concordance. Furthermore, the concordance of cfDNA levels at any time point of 359 therapy using both methods also showed a good concordance. Therefore, both methods 360 could be used to robustly measure the cfDNA content. However, to complete our study 361 we chose the qPCR assay, which is a high sensitive and specific assay for cfDNA 362 quantification in SCLC patients, and was previously employed in studies focused on 363 non-small cell lung cancer (45–48).

364 Regarding the clinical meaning of cfDNA content, we found that high levels were 365 significantly associated with shorter PFS and OS before therapy onset, being a robust 366 independent prognostic biomarker in newly diagnosed SCLC patients. Also, cfDNA 367 levels at baseline were higher in patients with stage IV that could be a consequence of 368 more aggressive disease. This can be partially explained by an increase of ctDNA levels 369 released from the tumor cells to the bloodstream, increasing the total cfDNA fraction. 370 Moreover, analyses showed that changes of cfDNA levels between baseline and 3 371 weeks are associated with patients' outcomes, being those patients with high values in 372 both sample points, the ones with the worst prognosis. In addition, high cfDNA levels at

373 the time of disease recurrence were associated with a higher risk of death. Of note, 374 multivariate analyses showed the independence of cfDNA levels at 3 weeks and at 375 progression disease as a prognostic biomarker. These results suggest that cfDNA 376 monitoring could provide valuable information for the management of SCLC as our 377 group previously reported in non-small cell lung cancer (NSCLC) (29). Thus, in 378 clinical practice, in those SCLC patients with high levels of cfDNA at the time of 379 disease recurrence, the selection of a more aggressive therapy or the intensification of 380 clinical visits would be considered.

381 Besides cfDNA levels, we investigated the prognostic value of additional biomarkers 382 such as CTCs and clinical characteristics. CTCs were analyzed in a cohort of 21 SCLC 383 patients using the CellSearch® system, the only Food and Drug Administration (FDA)-384 approved device for CTC enumeration in prostate, breast and colorectal cancer. 385 According to previous studies (16), a detection rate of 85.71% was found in our study. 386 Moreover, the CTC count at baseline determined using the CellSearch® system was 387 significantly associated with PFS and OS (24,27,28,49,50). For example, Naito et al. 388 reported that the presence of ≥ 8 CTCs/7.5mL of blood was associated with worse OS 389 (24), however, another study employed 50 CTCs as cut-off for PFS and OS (28). In fact, 390 a consensus regarding the optimal cut-off of CTCs and the prognostic value remains a 391 challenge (16). In this work, we found a discrete association between the presence of 392 \geq 150 CTCs and a shorter PFS, however multivariate analyses did not show independent 393 value for the CTC count. Interestingly, high cfDNA levels and the presence of CTCs at 394 baseline were significantly associated, reporting the clear association between both 395 circulating biomarkers. CTCs release in the bloodstream is related to the intravasation 396 process of potentially metastatic cancer cells. Nevertheless, cfDNA is released by any 397 cell type including tumoral and normal cells, however, how cfDNA release relates to

398 tumor biology is currently unknown. Finally, we evaluate several factors that could 399 influence the patients' outcomes. Thus, we proposed a simple model to segregate 400 patients into three categories based on risk of progression and death (taking into account 401 the cfDNA levels, ECOG and gender of patients). We found that patients with one or 402 less adverse prognostic factors were classified in the favorable-risk category and present 403 a longer PFS and OS. Thinking about the clinical relevance of these results, some 404 limitations in our design should be considered. First, the sample size of our CTC cohort 405 was relatively small and CTC monitoring during therapy could provide more valuable 406 information. Finally, a validation study of our prognostic model in a larger cohort of 407 patients can arise more robust conclusions.

In conclusion, we describe an important potential role of cfDNA levels as a prognostic biomarker in newly diagnosed SCLC patients and also could provide useful information about disease evolution. In addition, a prognostic model employing cfDNA levels and some clinical characteristics (ECOG and gender) allow us to stratify patients and detect those who particularly could benefit from treatment.

413

415 Acknowledgments

416 This project never could be possible without the kindly collaboration of all patients.

417 Author's contributions

- 418 All authors agreed to submit this manuscript. L.L-M., L.M-R., R.L-L and R.D-P.
- 419 designed and supervised the project. M.M-P., J.G-G. and L.L-M. contributed clinical
- 420 samples and patient characteristics. P.M-M and A.A performed experiments. P.M-M.
- 421 and R.D-P analyzed the data. P.M-M. and R.D-P prepared the manuscript. L.M-R. and
- 422 L.L-M supervised the manuscript. All the authors read and approved the final
- 423 manuscript.

424 Ethics approval and consent to participate

425 The present study was approved by the ethic committee of Santiago de Compostela and

426 Lugo Ethics Committee (Ref: 2017/538). Written informed content was obtained from

427 every participant prior to enrolling in the study and could withdraw their consent at any

428 time. The study was performed in accordance with the Declaration of Helsinki.

429 **Consent for publication**

430 Not applicable.

431 Data availability

432 The data that support the findings of this study are available from the corresponding433 author upon reasonable request.

434 Competing interest

435 Jorge García-González reports personal fees from AstraZeneca, Boehringer-Ingelheim,

436 Novartis, Pierre Fabre, Rovi and Sanofi; and personal fees and non-financial support

- 437 from Bristol-Myers Squibb, Lilly, MSD and Roche, outside the submitted work. Luis
- 438 <u>León-Mateos</u> reports personal fees from AstraZeneca, Boehringer-Ingelheim, Novartis,

Jansen, Astellas and Sanofi; and personal fees and non-financial support from BristolMyers Squibb, Lilly, MSD and Roche, outside the submitted work. <u>Rafael López-López</u>
reports grants and personal fees from Roche, Merck, AstraZeneca, Bayer, Pharmamar,
Leo, and personal fees and non-financial support from Bristol-Myers Squibb and
Novartis, outside of the submitted work. The other authors declare no competing
interests.

445 **Funding information**

This study was financed by all the donors who participated in the Liquid Biopsy
Crowdfunding campaign in 2017. LMR is funded by a contract "Miguel Servet" from
ISCIII (CP20/00120). RDP is funded by a contract "Miguel Servet" from ISCIII
(CP21/00003).

Rudin CM, Brambilla E, Faivre-Finn C, Sage J. Small-cell lung cancer. Nat Rev

451 **References**

1.

| 453 | | Dis Prim. 2021 Dec 14;7(1):3. |
|-----|----|---|
| 454 | 2. | Thai AA, Solomon BJ, Sequist L V., Gainor JF, Heist RS. Lung cancer. Lancet. |
| 455 | | 2021;398(10299):535–54. |
| 456 | 3. | Gazdar AF, Bunn PA, Minna JD. Small-cell lung cancer: What we know, what |
| 457 | | we need to know and the path forward. Nat Rev Cancer. 2017;17(12):725–37. |
| 458 | 4. | Esposito G, Palumbo G, Carillio G, Manzo A, Montanino A, Sforza V, et al. |
| 459 | | Immunotherapy in Small Cell Lung Cancer. Cancers (Basel). 2020 Sep 4 [cited |
| 460 | | 2020 Oct 15];12(9):2522. |
| 461 | 5. | Facchinetti F, Di Maio M, Tiseo M. Adding PD-1/PD-L1 inhibitors to |
| 462 | | chemotherapy for the first-line treatment of extensive stage small cell lung cancer |
| 463 | | (Sclc): A meta-analysis of randomized trials. Vol. 12, Cancers. MDPI AG; 2020. |
| 464 | | p. 1–18. |
| 465 | 6. | Horn L, Mansfield AS, Szczęsna A, Havel L, Krzakowski M, Hochmair MJ, et |
| 466 | | al. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell |
| 467 | | Lung Cancer. N Engl J Med. 2018 Dec;379(23):2220-9. |
| 468 | 7. | Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, et al. |
| 469 | | Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line |
| 470 | | treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, |
| 471 | | controlled, open-label, phase 3 trial. Lancet [Internet]. 2019 Nov |
| 472 | | 23;394(10212):1929–39. |
| 473 | 8. | Rudin CM, Awad MM, Navarro A, Gottfried M, Peters S, Csőszi T, et al. |
| 474 | | Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy |
| 475 | | for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase |
| | | |

| 476 | | III KEYNOTE-604 Study. J Clin Oncol. 2020 Jul 20;38(21):2369–79. |
|-----|-----|---|
| 477 | 9. | Dumoulin DW, Dingemans AMC, Aerts JGJV, Remon J, de Ruysscher DKM, |
| 478 | | Hendriks LEL. Immunotherapy in small cell lung cancer: One step at a time: A |
| 479 | | narrative review. Transl Lung Cancer Res. 2021;10(6):2970-87. |
| 480 | 10. | George J, Lim JS, Jang SJ, Cun Y, Ozretić L, Kong G, et al. Comprehensive |
| 481 | | genomic profiles of small cell lung cancer. Nature. 2015 Aug;524(7563):47-53. |
| 482 | 11. | Kalemkerian GP, Loo BW, Akerley W, Attia A, Bassetti M, Boumber Y, et al. |
| 483 | | NCCN guidelines® insights: Small cell lung cancer, version 2.2018 featured |
| 484 | | updates to the NCCN guidelines. JNCCN J Natl Compr Cancer Netw. |
| 485 | | 2018;16(10):1171-82. |
| 486 | 12. | Ortega-Franco A, Ackermann C, Paz-Ares L, Califano R. First-line immune |
| 487 | | checkpoint inhibitors for extensive stage small-cell lung cancer: clinical |
| 488 | | developments and future directions. ESMO Open. 2021;6(1):100003. |
| 489 | 13. | Blackhall F, Frese KK, Simpson K, Kilgour E, Brady G, Dive C. Will liquid |
| 490 | | biopsies improve outcomes for patients with small-cell lung cancer? Lancet |
| 491 | | Oncol. 2018 Sep 1;19(9):e470-81. |
| 492 | 14. | Cheng ML, Pectasides E, Hanna GJ, Parsons HA, Choudhury AD, Oxnard GR. |
| 493 | | Circulating tumor DNA in advanced solid tumors: Clinical relevance and future |
| 494 | | directions. CA Cancer J Clin. 2021;71(2):176–90. |
| 495 | 15. | Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, et al. |
| 496 | | Detection of circulating tumor DNA in early- and late-stage human malignancies. |
| 497 | | Sci Transl Med. 2014 Feb;6(224):224ra24. |
| 498 | 16. | Mondelo-Macía P, García-González J, León-Mateos L, Castillo-García A, López- |
| 499 | | López R, Muinelo-Romay L, et al. Current status and future perspectives of |
| 500 | | liquid biopsy in small cell lung cancer. Biomedicines. 2021;9(1):1-22. |

- 501 17. Keller L, Belloum Y, Wikman H, Pantel K. Clinical relevance of blood-based
- 502 ctDNA analysis: mutation detection and beyond. Br J Cancer. 2020.
- 503 18. Aucamp J, Bronkhorst AJ, Badenhorst CPS, Pretorius PJ. The diverse origins of
- 504 circulating cell-free DNA in the human body: a critical re-evaluation of the
- 505 literature. Biol Rev. 2018;93(3):1649–83.
- 506 19. Kustanovich A, Schwartz R, Peretz T, Grinshpun A. Life and death of circulating
 507 cell-free DNA. Cancer Biol Ther. 2019;20(8):1057–67.
- 508 20. Pantel K, Speicher MR. The biology of circulating tumor cells. Oncogene.
- 509 2016;35(10):1216–24.
- 510 21. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, et al.
- 511 Circulating tumor cells, disease progression, and survival in metastatic breast
- 512 cancer. N Engl J Med. 2004;351(8):781–91.
- 513 22. Cohen SJ, Punt CJA, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, et al.
- 514 Relationship of circulating tumor cells to tumor response, progression-free
- 515 survival, and overall survival in patients with metastatic colorectal cancer. J Clin
- 516 Oncol Off J Am Soc Clin Oncol. 2008 Jul;26(19):3213–21.
- 517 23. de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H, et al.
- 518 Circulating tumor cells predict survival benefit from treatment in metastatic
- 519 castration-resistant prostate cancer. Clin cancer Res an Off J Am Assoc Cancer
- 520 Res. 2008 Oct;14(19):6302–9.
- 521 24. Naito T, Tanaka F, Ono A, Yoneda K, Takahashi T, Murakami H, et al.
- 522 Prognostic impact of circulating tumor cells in patients with small cell lung
- 523 cancer. J Thorac Oncol. 2012;7(3):512–9.
- 524 25. Igawa S, Gohda K, Fukui T, Ryuge S, Otani S, Masago A, et al. Circulating
- 525 tumor cells as a prognostic factor in patients with small cell lung cancer. Oncol

| 526 | | Lett. 2014 May;7(5):1469–73. |
|-----|-----|--|
| 527 | 26. | Cheng Y, Liu XQ, Fan Y, Liu YP, Liu Y, Liu Y, et al. Circulating tumor cell |
| 528 | | counts/change for outcome prediction in patients with extensive-stage small-cell |
| 529 | | lung cancer. Futur Oncol. 2016;12(6):789–99. |
| 530 | 27. | Salgia R, Weaver RW, McCleod M, Stille JR, Yan SB, Roberson S, et al. |
| 531 | | Prognostic and predictive value of circulating tumor cells and CXCR4 expression |
| 532 | | as biomarkers for a CXCR4 peptide antagonist in combination with carboplatin- |
| 533 | | etoposide in small cell lung cancer: exploratory analysis of a phase II study. |
| 534 | | Invest New Drugs. 2017;35(3):334–44. |
| 535 | 28. | Aggarwal C, Wang X, Ranganathan A, Torigian D, Troxel A, Evans T, et al. |
| 536 | | Circulating tumor cells as a predictive biomarker in patients with small cell lung |
| 537 | | cancer undergoing chemotherapy. Lung Cancer. 2017 Oct;112:118-25. |
| 538 | 29. | Mondelo-Macía P, García-González J, León-Mateos L, Anido U, Aguín S, |
| 539 | | Abdulkader I, et al. Clinical potential of circulating free DNA and circulating |
| 540 | | tumour cells in patients with metastatic non-small-cell lung cancer treated with |
| 541 | | pembrolizumab. Mol Oncol. 2021;15(11):2923-40. |
| 542 | 30. | Akaike H. A New Look at the Statistical Model Identification. In 1974. p. 215- |
| 543 | | 22. |
| 544 | 31. | Therneau TM, Grambsch PM. Modeling Survival Data: Extending the Cox |
| 545 | | Model. New York: Springer; 2000. |
| 546 | 32. | Hadley W. Ggplot2: Elegrant graphics for data analysis. Springer; 2016. |
| 547 | 33. | Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez J-C, et al. pROC: |
| 548 | | an open-source package for R and S+ to analyze and compare ROC curves. BMC |
| 549 | | Bioinformatics. 2011 Dec 17;12(1):77. |
| 550 | 34. | Sjoberg, Daniel D, Whiting K, Curry M, Lavery, Jessica A, Larmarange J. |

| 551 | | Reproducible Summary Tables with the gtsummary Package. R J. |
|-----|-----|--|
| 552 | | 2021;13(1):570. |
| 553 | 35. | Oliveira KCS, Ramos IB, Silva JMC, Barra WF, Riggins GJ, Palande V, et al. |
| 554 | | Current Perspectives on Circulating Tumor DNA, Precision Medicine, and |
| 555 | | Personalized Clinical Management of Cancer. Mol Cancer Res. 2020 |
| 556 | | Apr;18(4):517–28. |
| 557 | 36. | Schwendenwein A, Megyesfalvi Z, Barany N, Valko Z, Bugyik E, Lang C, et al. |
| 558 | | Molecular profiles of small cell lung cancer subtypes: therapeutic implications. |
| 559 | | Mol Ther - Oncolytics. 2021;20(March):470-83. |
| 560 | 37. | Yang S, Zhang Z, Wang Q. Emerging therapies for small cell lung cancer. J |
| 561 | | Hematol Oncol. 2019 May;12(1):47. |
| 562 | 38. | Leon SA, Shapiro B, Sklaroff DM, Yaros MJ. Free DNA in the serum of cancer |
| 563 | | patients and the effect of therapy. Cancer Res. 1977 Mar;37(3):646-50. |
| 564 | 39. | van der Drift MA, Hol BEA, Klaassen CHW, Prinsen CFM, van Aarssen |
| 565 | | YAWG, Donders R, et al. Circulating DNA is a non-invasive prognostic factor |
| 566 | | for survival in non-small cell lung cancer. Lung Cancer. 2010 May;68(2):283-7. |
| 567 | 40. | Almodovar K, Iams WT, Meador CB, Zhao Z, York S, Horn L, et al. |
| 568 | | Longitudinal cell-free DNA analysis in patients with small cell lung cancer |
| 569 | | reveals dynamic insights into treatment efficacy and disease relapse. |
| 570 | | 2018;13(1):112–23. |
| 571 | 41. | Nong J, Gong Y, Guan Y, Yi X, Yi Y, Chang L, et al. Circulating tumor DNA |
| 572 | | analysis depicts subclonal architecture and genomic evolution of small cell lung |
| 573 | | cancer. Nat Commun. 2018;9(1):1–8. |
| 574 | 42. | Du M, Thompson J, Fisher H, Zhang P, Huang CC, Wang L. Genomic alterations |
| 575 | | of plasma cell-free DNAs in small cell lung cancer and their clinical relevance. |

576 Lung Cancer. 2018;120:113–21.

- 43. Mohan S, Foy V, Ayub M, Leong HS, Schofield P, Sahoo S, et al. Profiling of
- 578 Circulating Free DNA Using Targeted and Genome-wide Sequencing in Patients
- 579 with SCLC. J Thorac Oncol. 2020;15(2):216–30.
- 580 44. Iams WT, Kopparapu PR, Yan Y, Muterspaugh A, Zhao Z, Chen H, et al. Blood-
- 581 Based Surveillance Monitoring of Circulating Tumor DNA From Patients With
- 582 SCLC Detects Disease Relapse and Predicts Death in Patients With Limited-
- 583 Stage Disease. JTO Clin Res Reports. 2020;1(2):100024.
- 584 45. Mondelo-Macía P, García-González J, León-Mateos L, Anido U, Aguín S,
- 585 Abdulkader I, et al. Clinical potential of circulating free DNA and circulating
- 586 tumour cells in patients with metastatic non-small cell lung cancer treated with
- 587 pembrolizumab. Mol Oncol. 2021;
- 46. Alama, Coco, Genova, Rossi, Fontana, Tagliamento, et al. Prognostic Relevance
 of Circulating Tumor Cells and Circulating Cell-Free DNA Association in
- 590Metastatic Non-Small Cell Lung Cancer Treated with Nivolumab. J Clin Med.
- 591 2019;8(7):1011.
- 592 47. Sirera R, Bremnes RM, Cabrera A, Jantus-Lewintre E, Sanmartín E, Blasco A, et
- al. Circulating DNA is a useful prognostic factor in patients with advanced non-
- small cell lung cancer. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer.
 2011 Feb;6(2):286–90.
- 596 48. Paci M, Maramotti S, Bellesia E, Formisano D, Albertazzi L, Ricchetti T, et al.
- 597 Circulating plasma DNA as diagnostic biomarker in non-small cell lung cancer.
 598 Lung Cancer. 2009 Apr;64(1):92–7.
- 599 49. Hou JM, Greystoke A, Lancashire L, Cummings J, Ward T, Board R, et al.
- 600 Evaluation of circulating tumor cells and serological cell death biomarkers in

- 601 small cell lung cancer patients undergoing chemotherapy. Am J Pathol.
- 602 2009;175(2):808–16.
- 603 50. Hou JM, Krebs MG, Lancashire L, Sloane R, Backen A, Swain RK, et al.
- 604 Clinical significance and molecular characteristics of circulating tumor cells and
- 605 circulating tumor microemboli in patients with small-cell lung cancer. J Clin
- 606 Oncol. 2012;30(5):525–32.
- 607
- 608

FIGURES

Figure 1. Study schema and clinical course of all patients included in the study. (A) Study sampling points and cohorts. (B) Swimmers' plot showing each patient therapy and the different times of sample collection. The total length of each bar indicates the

duration of survival from the diagnoses. Abbreviations: SCLC, small-cell lung cancer;

- CTCs, circulating tumor cells; cfDNA: cell free DNA.



638 Figure 2. (A) Correlation between cfDNA levels using Qubit method and qPCR assay at different times of therapy (baseline, 3 weeks and progression disease). (B-C) Total 639 640 cfDNA levels in healthy controls and patients with SCLC. (D-E) ROC curves for Oubit 641 method (C) and qPCR assay (E) show high sensitivity and specificity to discriminate 642 healthy controls and SCLC patients. Abbreviations: cfDNA, cell free DNA; GE, 643 genomic equivalents; AUC, area under the curve; CI, confidence interval.



medRxiv preprint doi: https://doi.org/10.1101/2022.03.25.22272967; this version posted March 27, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. All rights reserved. No reuse allowed without permission.

667 Figure 3. CfDNA levels as a prognostic biomarker at different time points of therapy. (A-B) Kaplan-Meier survival analysis of cfDNA levels at baseline for PFS (A) and OS 668 669 (B). (C-D) Kaplan-Meier survival analysis of cfDNA levels at 3 weeks for PFS (C) and OS (D). (E) Kaplan-Meier survival analysis of cfDNA levels at progression disease for 670 OS. Abbreviations: cfDNA, cell free DNA; OS, overall survival; PFS, progression-free 671 672 survival; PD: progression disease.



perpetuity. All rights reserved. No reuse allowed without permission.

Figure 4. (A) Final multivariate Cox regression prognostic model for PFS and OS. (BC) Kaplan-Meier survival analysis according to risk-group for PFS and OS.
Abbreviations: cfDNA, cell free DNA; ECOG, Eastern Cooperative Oncology Group
Performance Score, PFS, progression-free survival; OS, overall survival; HR, hazard
ratio; CI, confidence interval.



722 TABLES

723

724 **Table 1.** Association between patients' demographics/clinical characteristics and 725 baseline cfDNA levels.

| Characteristics | Baseline cfDNA, median (GE/ml) | <i>p</i> -value |
|--|--------------------------------------|-----------------------|
| Age, 67, 66.83 ± 8.1, 47-83 (Median, Mean age ± SD, range) | | |
| Bellow median, n=24 (52.17%) | 6488.23 | 0.79 |
| Above median, n=22 (47.82%) | 8403.79 | |
| Gender | | |
| Male, n=39 (84.78%) | 6130.59 | 0.61 |
| Female, n=7 (15.22%) | 15699.93 | |
| Stage | | |
| III, n=5 (10.87%) | 1409.11 | 0.031 |
| IV, n=41 (89.13%) | 7658.99 | |
| ECOG PS | | |
| < 2, n=31 (67.39%) | 4652.13 | 0.025 |
| \geq 2, n=15 (32.61%) | 22459.61 | |
| Smoking | | |
| Smoker, n=26 (56.52%) | 6488.23 | 0.94 |
| Former smoker, n=20 (43.48%) | 6155.56 | |
| Number of metastasis | | |
| $\leq 2, n=22 (47.82\%)$ | 4563.83 | 0.05 |
| > 2, n=24 (52.17%) | 12973.33 | |
| Liver metastases | | |
| No, n=23 (50.0%) | 3355.91 | 2.20x10 ⁻⁴ |

| | Yes, n=23 (50.0%) | 24759.83 | |
|--|--|----------|------|
| | Bone metastases | | |
| | No, n=18 (39.13%) | 3265.055 | 0.17 |
| | Yes, n=28 (60.87%) | 3355.91 | |
| | Lymph node metastases | | |
| | No, n=10 (21.74%) | 4563.83 | 0.12 |
| | Yes, n=36 (78.26%) | 7658.99 | |
| | Treatment | | |
| | Chemotherapy, n=33 (71.74%) | 6130.59 | 0.36 |
| | Chemotherapy plus Immunotherapy, n=13 (28.26%) | 10676.99 | |
| 728 729 730 731 732 733 734 735 736 737 738 739 740 741 742 743 744 745 746 747 748 749 | | | |

- 751 752
- 753

| Variable | Univariate | | Multivar | riate |
|--|------------|------------------|----------|------------------|
| | | HR | | HR |
| | p-value | (95% CI) | p-value | (95% CI) |
| PFS | | | | |
| Baseline log cfDNA (high vs. low cfDNA) | 0.001 | 5.06 (1.89-13.6) | 0.005 | 46.0 (3.16-672) |
| Baseline CTC count, CellSearch (≥150 vs. | 0.028 | 3.47 (1.14-10.6) | | |
| <150) | | | | |
| ECOG (≥2 vs. <2) | < 0.001 | 3.57 (1.72-7.40) | 0.04 | 17.9 (1.11-289) |
| Sex (male vs. female) | 0.2 | 1.76 (0.74-4.22) | | |
| Age (continue) | 0.5 | 1.01 (0.97-1.05) | | |
| Stage (IV vs. III) | 0.07 | 3.00 (0.91-9.91) | | |
| Number of metastasis (>2 vs. \leq 2) | 0.1 | 1.70 (0.90-3.19) | | |
| Liver metastasis (yes vs. no) | 0.08 | 1.74 (0.93-3.23) | | |
| Smoking (smoker vs. former smoker) | 0.8 | 0.92 (0.49-1.70) | | |
| 3 weeks log cfDNA (high vs. low cfDNA)* | < 0.0001 | 3.50 (1.69-7.23) | 0.004 | 3.49 (1.50-8.12) |
| <u>OS</u> | | | | |
| Baseline log cfDNA (high vs. low cfDNA) | 0.003 | 3.32 (1.50-7.37) | 0.004 | 32.4 (3.05-344) |
| Baseline CTC count, CellSearch (≥150 vs. | 0.07 | 2.71 (0.93-7.88) | | |
| <150) | | | | |
| ECOG (≥2 vs. <2) | < 0.001 | 4.54 (2.13-9.68) | | |
| Sex (male vs. female) | 0.2 | 1.80 (0.75-4.36) | | |
| Age (continue) | 0.5 | 1.01 (0.97-1.06) | | |

Table 2. Univariate and multivariate Cox regression analyses of cfDNA levels, CTC 754 counts and clinical parameters. 755

 medRxiv preprint doi: https://doi.org/10.1101/2022.03.25.22272967; this version posted March 27, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

 All rights reserved. No reuse allowed without permission.

 Stage (IV vs. III)
 0.08
 2.86 (0.86-9.47)

| - | | | | | |
|---|---------|------------------|-------|------------------|--|
| Number of metastasis (>2 vs. ≤2) | 0.5 | 1.23 (0.65-2.33) | | | |
| Liver metastasis (yes vs. no) | 0.3 | 1.45 (0.77-2.76) | | | |
| Smoking (smoker vs. former smoker) | 0.5 | 0.82 (0.43-1.55) | | | |
| 3 weeks log cfDNA (high vs. low cfDNA)* | < 0.001 | 3.67 (1.72-7.82) | 0.002 | 4.35 (1.68-11.3) | |
| PD log cfDNA (high vs. low cfDNA)* | < 0.001 | 15.2 (3.28-70.7) | 0.001 | 19.5 (3.30-115) | |

756

*Multivariate Cox regression model including sex, age, Eastern Cooperative Oncology
Group Performance Score, stage, number of metastases, presence of liver metastasis and
smoking status. The levels of cfDNA were determined as low (<cut-off) or high (≥cut-
off) based on the cut-off obtained from the ROC curve analyses. Abbreviations: cfDNA,
cell free DNA; CTC, circulating tumor cell; ECOG, Eastern Cooperative Oncology
Group Performance Score; PFS, progression-free survival; OS, overall survival; HR,
hazard ratio; CI, confidence interval.